

# 1 Appendix B: Guideline scope

## 2 B.1 Guideline title

3 Cataracts in adults: management

### 4 B.1.1 Short title

5 Cataracts in adults: management

### 6 B.1.2 Topic

7 The Department of Health in England has asked NICE 'to develop a clinical guideline on  
8 Cataracts: diagnosis and management of cataracts' and to consider issues surrounding  
9 'indications for cataract extraction' and 'wrong lens implant errors'.

### 10 B.1.3 Who the guideline is for

- 11 • people using services, families and carers and the public
- 12 • healthcare professionals in primary care
- 13 • healthcare professionals in secondary care
- 14 • social care practitioners
- 15 • local authorities
- 16 • commissioners of ophthalmic and optometric services
- 17 • providers of ophthalmic and optometric services
- 18 • practitioners in ophthalmic and optometric services.

19 It may also be relevant for:

- 20 • private sector and voluntary organisations
- 21 • people working in related services.

22 NICE guidelines cover health and care in England. Decisions on how they apply in other UK  
23 countries are made by ministers in the Welsh Government, Scottish Government, and  
24 Northern Ireland Executive.

## 25 B.2 Equality considerations

26 NICE has carried out [an equality impact assessment](#) [link in final version] during scoping.  
27 The assessment:

- 28 • lists equality issues identified, and how they have been addressed
- 29 • explains why any groups are excluded from the scope, if this was done.

## 30 B.3 What the guideline is about

### 31 B.3.1 Who is the focus?

#### 32 Groups that will be covered

- 33 • Adults (18 years and older) diagnosed with cataracts.
- 34 • The following subgroups have been identified as needing specific consideration:

- 35           ○ people with other conditions that may affect management, including people who are  
 36           frail, older people, people with impaired cognitive function, people with impaired  
 37           mobility, people in residential care and people with learning disabilities.
- 38           ● The following subgroups will be considered where appropriate:
- 39           ○ people with an ocular or systemic condition that affects perioperative management,  
 40           including people with diabetes, uveitis, glaucoma, retinal disease, macular  
 41           degeneration, Fuch's corneal endothelial dystrophy, high myopia, hypermetropia and  
 42           iris defects
- 43           ○ people who are using medicines that affect perioperative management, including  
 44           aspirin, oral anticoagulants, low-molecular-weight heparins, alpha antagonists and  
 45           prostaglandin analogues.

46           **Groups that will not be covered**

- 47           ● Children and young people under 18 years with congenital and/or juvenile cataracts,  
 48           because the management pathway and issues associated with cataracts are very different  
 49           in this group compared with adults.
- 50           ● People with trauma-induced cataracts, who have other pathologies related to the injury.

51           **B.4 Settings**

52           **Settings that will be covered**

- 53           ● All settings in which NHS-funded health and social care is received.

54           **Settings that will not be covered**

- 55           ● Elective privately funded surgery.

56           **B.5 Activities, services or aspects of care**

57           **Key areas that will be covered**

- 58           1. Information and support for people with cataracts and their carers.
- 59           2. Management
- 60           ○ Indications and clinical thresholds for referral for surgical treatment.
- 61           ○ Optimal preoperative assessment strategies in cataract extraction. Specific aspects  
 62           that will be considered are biometry and risk stratification techniques.
- 63           ○ Optimal treatment strategies in cataract surgery. Specific aspects that will be  
 64           considered are: surgical procedures; type and administration of anaesthesia; selection  
 65           and types of intraocular lens (it is proposed that this would include evaluating the  
 66           effectiveness of multifocal [non-accommodative] intraocular lenses [subject to approval  
 67           by NICE's Guidance Executive]). Note that guideline recommendations will normally fall  
 68           within licensed indications; exceptionally, and only if clearly supported by evidence, use  
 69           outside a licensed indication may be recommended. The guideline will assume that  
 70           prescribers will use a medicine's summary of product characteristics to inform  
 71           decisions made with individual patients.
- 72           ○ Cataract surgery for people with astigmatism, specifically the use of toric intraocular  
 73           lenses and limbal relaxing incisions.
- 74           ○ Cataract surgery for people with high myopia, specifically interventions to prevent  
 75           retinal detachment.
- 76           ○ Second eye surgery. Specific aspects that will be considered are timing and visual  
 77           acuity level.

- 78 ○ Optimal treatment strategies to prevent complications and errors in cataract surgery.  
 79 Specific aspects that will be considered are: interventions to prevent intraoperative  
 80 complications; use of postoperative eye shields; use, administration and timing of  
 81 antibiotics to minimise the risk of infection; use, administration and timing of topical  
 82 corticosteroids and/or NSAIDs (non-steroidal anti-inflammatory drugs) to control  
 83 postoperative inflammation and cystoid macular oedema; strategies to reduce the risk  
 84 of wrong lens implant errors. Note that guideline recommendations will normally fall  
 85 within licensed indications; exceptionally, and only if clearly supported by evidence, use  
 86 outside a licensed indication may be recommended. The guideline will assume that  
 87 prescribers will use a medicine's summary of product characteristics to inform  
 88 decisions made with individual patients.
- 89 ○ Management of operative complications, specifically interventions to manage  
 90 perioperative posterior capsule rupture and postoperative cystoid macular oedema.
- 91 3. Ongoing care
- 92 ○ Optimal postoperative follow-up strategies, including: timing and setting of  
 93 postoperative assessment and care; healthcare professionals undertaking  
 94 postoperative assessment and care; and strategies to effectively communicate  
 95 outcomes between surgical units and providers of postoperative assessment and care.

### 96 **Areas that will not be covered**

- 97 1. Training and competency in specialist cataract surgery.  
 98 2. Access to general optometric care.  
 99 3. Processes for assessing and implementing new technology.  
 100 4. Diagnosis of cataracts. Following stakeholder consultation, no specific issues in terms of  
 101 diagnosing the presence of cataracts were identified because the procedures and  
 102 assessments were considered straightforward.  
 103 5. Interventions to prevent the development and progression of cataracts, including  
 104 supplements such as vitamins, omega fatty acids, lutein and zeaxanthin, and lifestyle  
 105 changes such as advice to stop smoking and minimise sun exposure.  
 106 6. Surgical interventions that are not used in England, including small incision extracapsular  
 107 cataract extraction.  
 108 7. Additional surgical interventions for conditions other than cataracts, including concurrent  
 109 procedures such as vitreoretinal surgery and glaucoma surgery.

## 110 **B.6 Economic aspects**

111 We will take economic aspects into account when making recommendations. We will develop  
 112 an economic plan that states for each review question (or key area in the scope) whether  
 113 economic considerations are relevant, and if so whether this is an area that should be  
 114 prioritised for economic modelling and analysis. We will review the economic evidence and  
 115 carry out economic analyses. The reference case used will be that for interventions with  
 116 health outcomes in NHS settings; therefore the preferred unit of effectiveness will be the  
 117 quality-adjusted life year (QALY), and costs will be considered from an NHS and personal  
 118 social services (PSS) perspective.

## 119 **B.7 Key issues and questions**

120 While writing this scope, we have identified the following key issues, and review questions  
 121 related to them:

- 122 1. Information and support for people with cataracts and their carers
- 123 ○ What information do people with cataracts and their carers find useful, and what format  
 124 (for example written or verbal) do they prefer it to be provided in?

- 125           ○ What information on cataract surgery (before, during and after the operation) do people  
 126           and their carers find useful, and what format (for example written or verbal) do they  
 127           prefer it to be provided in?
- 128           2. Indications and clinical thresholds for referral for surgical treatment after initial  
 129           presentation to the optometrist or GP
- 130           ○ What are the indicators for referral for cataract surgery?
- 131           ○ What are the optimal clinical thresholds in terms of severity and impairment for referral  
 132           for cataract surgery?
- 133           3. Optimal preoperative assessment strategies in cataract extraction
- 134           ○ What is the effectiveness of different techniques for undertaking biometry?
- 135           ○ What are the most appropriate formulae to optimise intraocular lens biometry  
 136           calculation?
- 137           ○ How can biometry and postoperative refractive errors be reduced?
- 138           ○ What is the effectiveness of risk stratification techniques to reduce surgical  
 139           complications and errors?
- 140           4. Optimal treatment strategies in cataract surgery
- 141           ○ What is the effectiveness of laser phacoemulsification compared with ultrasound  
 142           phacoemulsification?
- 143           ○ What is the optimal type and administration of anaesthesia for cataract surgery?
- 144           ○ What is the optimal strategy when selecting intraocular lenses (for example, different  
 145           vision in both eyes or same vision in both eyes)?
- 146           ○ What is the effectiveness of aspheric monofocal lenses compared with spheric  
 147           monofocal lenses in cataract surgery?
- 148           ○ What is the effectiveness of square-edged monofocal lenses compared with standard  
 149           monofocal lenses in cataract surgery?
- 150           ○ What is the comparable effectiveness of foldable monofocal lenses that are hydrophilic  
 151           acrylic, hydrophobic acrylic, collagen or hydroxyethyl methacrylate-based compared  
 152           with silicone-based foldable monofocal lenses?
- 153           ○ What is the effectiveness of multifocal intraocular lenses compared with standard  
 154           monofocal lenses?
- 155           5. Cataract surgery for people with astigmatism
- 156           ○ What is the effectiveness of toric intraocular lenses compared with standard monofocal  
 157           lenses for people with cataracts and astigmatism?
- 158           ○ What is the effectiveness of limbal relaxing incisions compared with toric intraocular  
 159           lenses for people with cataracts and astigmatism?
- 160           6. Cataract surgery for people with high myopia
- 161           ○ What is the effectiveness of interventions (for example, prophylactic laser surgery) to  
 162           prevent retinal detachment in people with cataracts and high myopia?
- 163           7. Second eye surgery
- 164           ○ What is the effectiveness of bilateral simultaneous (rapid sequential) cataract surgery  
 165           compared with unilateral eye surgery?
- 166           ○ What is the optimal timing of second eye surgery, taking into account issues of  
 167           refractive power after first eye surgery?
- 168           8. Optimal treatment strategies to prevent complications and errors in cataract surgery
- 169           ○ In what circumstances are capsular tension rings effective?
- 170           ○ In what circumstances are interventions to increase pupil size effective?
- 171           ○ What is the effectiveness of postoperative eye shields to prevent complications after  
 172           cataract extraction?

- 173 ○ What is the effectiveness of different prophylactic antibiotics to prevent infection after  
174 cataract surgery?
- 175 ○ What is the optimal timing to administer prophylactic antibiotics to prevent infection  
176 after cataract surgery?
- 177 ○ What is the effectiveness of antibiotics combined with topical corticosteroids and/or  
178 NSAIDs compared with antibiotics alone to prevent infection after cataract surgery?
- 179 ○ What is the effectiveness of prophylactic topical corticosteroids and/or NSAIDs to  
180 prevent inflammation and cystoid macular oedema after cataract surgery?
- 181 ○ What are the procedural causes of wrong lens implant errors?
- 182 ○ What strategies should be adopted to reduce the risk of wrong lens implant errors?
- 183 9. Management of operative complications
- 184 ○ What is the effectiveness of interventions to reduce the impact of perioperative  
185 posterior capsule rupture?
- 186 ○ What is the effectiveness of interventions used to manage cystoid macular oedema  
187 after cataract surgery?
- 188 10. Optimal postoperative follow-up strategies
- 189 ○ What is the optimal time to assess outcomes in the postoperative period?
- 190 ○ Who and in what setting should carry out postoperative assessment and care?
- 191 ○ If postoperative assessment and care are undertaken outside of the hospital, how  
192 should outcomes between surgical units and these providers be effectively  
193 communicated?

## 194 **B.8 Main outcomes**

195 The main outcomes that will be considered when searching for and assessing the evidence  
196 are:

- 197 1. Unaided and best-corrected visual acuity (distance and near).
- 198 2. Contrast sensitivity.
- 199 3. Postoperative refractive outcomes.
- 200 4. Patient global improvement.
- 201 5. Patient independence (for example, activities of daily living, ability to drive).
- 202 6. Patient satisfaction.
- 203 7. Adverse effects of treatment, including complications of surgical interventions (for  
204 example, surgically induced astigmatism).
- 205 8. Accidents, including falls and traffic accidents.
- 206 9. Need for further treatment such as laser capsulotomy.
- 207 10. Health-related quality of life, including that of carers.
- 208 11. Resource use and costs.

## 209 **B.9 Links with other NICE guidance and NICE Pathways**

### 210 **B.9.1 NICE guidance**

#### 211 **NICE guidance about the experience of people using NHS services**

212 NICE has produced the following guidance on the experience of people using the NHS. This  
213 guideline will not include additional recommendations on these topics unless there are  
214 specific issues related to cataracts:

- 215 • [Medicines optimisation](#) (2015) NICE guideline NG5

- 216 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 217 • [Service user experience in adult mental health](#) (2011) NICE guideline CG136
- 218 • [Medicines adherence](#) (2009) NICE guideline CG76

## 219 **B.10 NICE Pathways**


220 When this guideline is published, the recommendations will be added to [NICE Pathways](#).  
221 NICE Pathways bring together all related NICE guidance and associated products on a topic  
222 in an interactive topic-based flow chart.

223 A draft pathway outline on cataracts, based on the draft scope, is included below. It will be  
224 adapted and more detail added as the recommendations are written during guideline  
225 development. The cataracts pathway will be accessible from the [eye conditions pathway](#).

226 Other relevant NICE guidance will also be added to the NICE Pathway, including:

- 227 • [Implantation of multifocal \(non-accommodative\) intraocular lenses during cataract surgery](#)  
228 (2008) NICE interventional procedure guidance IPG264
- 229 • [Implantation of accommodating intraocular lenses for cataract](#) (2007) NICE interventional  
230 procedure guidance IPG209

# Cataracts overview



231

## 232 B.11 Context

### 233 B.11.1 Key facts and figures

234 A cataract is defined as any opacity in the crystalline lens of the eye that can affect one or  
235 both eyes. The changes to the transparency and refractive index of the lens result in various  
236 levels of visual impairment. This impairment is associated with decreased quality of life,

- 237 because it may restrict the person's ability to carry out daily activities and function  
238 independently, while increasing the risk of accidents and falls.
- 239 Cataracts most commonly affect adults as a result of biological ageing (age-related  
240 cataracts) and may be classified according to the area of the lens that is affected (nuclear  
241 sclerotic, cortical or posterior subcapsular cataracts). Cataracts can also occur in children,  
242 and may be classified according to the age of onset (congenital or infantile/juvenile  
243 cataracts). Cataracts may occur secondary to hereditary factors, trauma, inflammation,  
244 metabolic or nutritional disorders and radiation. In addition, in adults, lifestyle factors such as  
245 tobacco smoking and high alcohol intake are associated with an increased risk of developing  
246 age-related cataracts.
- 247 Most of the studies on the prevalence and incidence of cataracts in adults and children in  
248 England and Wales were conducted more than 15 years ago. Proxy data on the frequency of  
249 cataract surgery indicate that, in 2012/13, a total of 340,809 operations were performed in  
250 England. This figure does not differentiate between first and second eye surgeries, but it is  
251 likely that most of these operations were performed on adults with age-related cataracts.
- 252 In adults, a greater prevalence of age-related cataracts is associated with being female,  
253 specific minority ethnic groups, including people of Asian, African and African–Caribbean  
254 family origin, people from low socioeconomic status groups, people with learning disabilities  
255 and people with comorbid conditions, including diabetes and uveitis.
- 256 Most cataracts are largely progressive, although the decline in visual function may be  
257 variable and unpredictable. The natural history of cataracts depends on the type and severity  
258 of cataract and the presence of ocular comorbid conditions. In severe untreated cases,  
259 cataracts can lead to blindness, which may be reversible with cataract surgery, although  
260 some level of visual impairment may persist.
- 261 Cataract surgery has a high success rate in improving visual function, with low morbidity and  
262 mortality. It is the commonest operation performed in the NHS, with an ever-growing need as  
263 the population ages. Guidance on clinical thresholds to access cataract surgery is needed to  
264 address patient need and to optimise the allocation of NHS resources. In addition, an  
265 understanding of the most clinically and cost-effective methods for undertaking cataract  
266 surgery, and to minimise complications and surgical errors such as wrong intraocular lens  
267 implants, is needed to further improve patient care.
- 268 **B.11.2 Current practice**
- 269 Cataract management usually involves a multidisciplinary team that includes  
270 ophthalmologists, optometrists, nurses and technicians.
- 271 Diagnosis is usually based on self-reported symptoms and a series of tests performed by an  
272 optometrist, normally based in the community. Symptoms may include blurred vision,  
273 difficulty seeing at night, sensitivity to light or glare, seeing 'halos' around lights and double  
274 vision in a single eye. Tests include a visual acuity test, and slit-lamp and retinal  
275 examinations.
- 276 In adults with early age-related cataracts, non-surgical management may include prescription  
277 of spectacles, bifocals or magnifying lenses, advice on the lighting of the reading  
278 environment and monitoring the progression of the condition. Alternatively, adults with age-  
279 related cataracts may be referred for surgery, by an optometrist or a GP. The clinical  
280 threshold used to access cataract surgery varies across NHS Trusts in England. This has  
281 resulted in differences in access to cataract surgery, since policies vary in scope and content  
282 and are not necessarily congruent with research evidence or guidance provided by the  
283 Department of Health in its document [Action on cataracts](#) and the Royal College of  
284 Ophthalmologists' [Cataract surgery guideline](#).



285 Because age-related cataracts have a higher prevalence with increasing age, consideration  
286 of people with other comorbidities that may affect management is needed, including frail  
287 people, older people, people with impaired cognitive function and people with impaired  
288 mobility.

### 289 **B.11.3 Policy, legislation, regulation and commissioning**

#### 290 **Policy**

291 This guideline will address areas highlighted in the [UK Vision Strategy 2013-2018](#), including  
292 improving awareness and understanding of eye health, access to eye care services to detect  
293 and prevent sight loss, the coordination, integration and effectiveness of eye health and care  
294 services, and consideration of equality issues.

#### 295 **Legislation, regulation and guidance**

296 The Department of Health's report [Action on cataracts](#) published in 2000, and the Royal  
297 College of Ophthalmologists' [Cataract surgery guidelines](#) published in 2010, provide  
298 guidance on various aspects of cataract management. This guideline will consider further  
299 controversial areas, including indicators for cataract surgery and second eye surgery, and  
300 examine in detail optimal treatment strategies for cataract operations. The guideline will also  
301 consider relevant guidance from the DVLA's [At a glance guide](#).

### 302 **B.12 Further information**

This is the final scope, incorporating comments from registered stakeholders during consultation.

The guideline is expected to be published in June 2017.

You can follow progress of the [guideline](#).

303